FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503115105> ?p ?o ?g. }

• W1503115105 abstract "Infantile seborrhoeic dermatitis (ISD) is a chronic, inflammatory, scaling skin condition, which causes redness and a greasy scaling rash in infants and young children. It can last from weeks to months, but rarely years. When it occurs on the scalp, it is referred to as 'cradle cap'. While benign and self-limiting, irrelevant of its location on the body, it can distress parents. The effectiveness of commonly promoted treatments is unclear.To assess the effects of interventions for infantile seborrhoeic dermatitis in children from birth to 24 months of age.We searched the following databases up to 22 May 2018: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched trials registers and checked reference lists of included studies for further references to randomised controlled trials (RCTs). We searched for unpublished RCTs and grey literature via web search engines, and wrote to authors and pharmaceutical companies.We included RCTs of interventions for ISD in children from birth up to 24 months who were clinically diagnosed by a healthcare practitioner with ISD or cradle cap. We allowed comparison of any treatment to no treatment or placebo, and the comparison of two or more treatments or a combination of treatments.We used standard methodological procedures expected by Cochrane. The primary outcome measures were 'Change in severity score from baseline to end of study' and 'Percentage of infants treated who develop adverse effects or intolerance to treatment'. The secondary outcome was 'Improvement in quality of life (QoL) as reported by parents'.We included six RCTs (one with a cross-over design) randomising 310 children and reporting outcomes for 297 children. Most participants were aged under seven months with only two participants aged over one year (seven and 12 years old); where specified, 60% were boys. In two studies, condition severity was mild to moderate; one study included two participants with severe ISD; the other studies did not describe baseline severity or described it as body surface area affected.The study setting was not always clear but likely a paediatric outpatient clinic in the following countries: Thailand, Israel, USA, France, and Australia.Two studies compared oral biotin (a B group vitamin) against placebo, two studies compared proprietary products against placebo cream or a control shampoo, and two studies compared topical corticosteroids against other products. The studies were generally short-term, between 10 and 42 days' duration; only one study followed the participants until resolution of the rash or eight months of age.We assessed the risk of bias as unclear for most aspects due to lack of reporting, but two of the studies were at high risk of performance and detection bias due to the appearance of the intervention, the trial design (open-label), or use of overlabelled tubes. Two trials had a high risk of attrition bias.All the results given below were based on very low-quality evidence. Treatment duration ranged from one week to three weeks.For the two trials comparing biotin versus placebo (n = 35), one did not report a measure of change in severity (only change in duration of rash) while the other did not report raw data (only 'no statistically significant difference'), measured at three weeks. Neither trial reported on adverse events.Two trials compared proprietary products against placebo (n = 160). One trial assessed change in severity via percentage success (96% of participants in non-steroidal cream Promiseb versus 92% in placebo), and reported no adverse events (both assessed at day 14). The other trial assessed change in severity via reduction in lesional score (surface area covered), finding better results for lactamide MEA gel (a moisturising agent) plus shampoo (81.4%) compared with shampoo only (70.2%; P = 0.0092). No adverse events were described, but signs of discomfort were similar in both groups (both assessed at day 21).In the comparison of topical steroids versus another product, change in severity was measured through evaluation of cure and body surface (n = 102).In one trial comparing hydrocortisone 1% lotion with licochalcone 0.025% lotion, there was no significant difference in participants cured (95.8% with hydrocortisone compared to 97.1% with licochalcone). One person in the licochalcone group developed more erythema, but there were no other adverse events (both outcomes assessed at day 14). In the trial comparing flumethasone pivalate 0.02% ointment versus eosin 2% aqueous solution, a reduction in body surface area affected was seen in both groups at day 10 (9% with corticosteroid versus 7% with aqueous solution), with all infants showing less than 10% involvement. There were no adverse events (both outcomes assessed at day 10).No studies measured QoL.We found no trials testing commonly used treatments such as mineral oils, salicylic acid, or antifungals.Our review identified only a limited number of studies investigating the effects of interventions for ISD in infants and young children. Unlike the reviews investigating the effects of treatments in adults, our results showed that there is uncertainty regarding the effectiveness and safety of studied treatments due to the very low-certainty evidence for all comparisons and outcomes.We assessed most bias domains as at unclear risk, but there was a high risk of bias for (mainly) performance, attrition, and detection bias. Evidence was limited further by imprecision (small studies, low number of events), indirectness (mainly with the outcomes assessed), and poor trial reporting. In most studies, the prognosis for the condition was favourable regardless of intervention but interpretation is limited by the very low-certainty evidence.Further research is needed with large, well-conducted, and well-reported intervention trials, particularly of interventions commonly recommended or used, such as emollients or shampoos and brushing, antifungals, or steroids. All studies should report standardised and validated relevant outcome measures, including adverse events, severity, and QoL, and they should be conducted in primary care settings where the majority of ISD is managed. Future trials should compare against placebo, no treatment, or standard care." @default.
• W1503115105 created "2016-06-24" @default.
• W1503115105 creator A5039039691 @default.
• W1503115105 creator A5043608283 @default.
• W1503115105 creator A5046401336 @default.
• W1503115105 creator A5054459051 @default.
• W1503115105 date "2019-03-04" @default.
• W1503115105 modified "2023-10-11" @default.
• W1503115105 title "Interventions for infantile seborrhoeic dermatitis (including cradle cap)" @default.
• W1503115105 cites W1493578925 @default.
• W1503115105 cites W1494993041 @default.
• W1503115105 cites W1503115105 @default.
• W1503115105 cites W1530442714 @default.
• W1503115105 cites W1567153585 @default.
• W1503115105 cites W1749838322 @default.
• W1503115105 cites W1767070301 @default.
• W1503115105 cites W1832830401 @default.
• W1503115105 cites W1905887921 @default.
• W1503115105 cites W1939887545 @default.
• W1503115105 cites W1969432375 @default.
• W1503115105 cites W1972440712 @default.
• W1503115105 cites W1979090453 @default.
• W1503115105 cites W1980156654 @default.
• W1503115105 cites W1984047108 @default.
• W1503115105 cites W1994758895 @default.
• W1503115105 cites W1999541518 @default.
• W1503115105 cites W2001908604 @default.
• W1503115105 cites W2008430959 @default.
• W1503115105 cites W2010632439 @default.
• W1503115105 cites W2010696390 @default.
• W1503115105 cites W2012713776 @default.
• W1503115105 cites W2013878471 @default.
• W1503115105 cites W2035057842 @default.
• W1503115105 cites W2040230447 @default.
• W1503115105 cites W2044280032 @default.
• W1503115105 cites W2049315066 @default.
• W1503115105 cites W2052421092 @default.
• W1503115105 cites W2068717533 @default.
• W1503115105 cites W2071082535 @default.
• W1503115105 cites W2076322157 @default.
• W1503115105 cites W2084803434 @default.
• W1503115105 cites W2094312065 @default.
• W1503115105 cites W2103936693 @default.
• W1503115105 cites W2105185553 @default.
• W1503115105 cites W2115544492 @default.
• W1503115105 cites W2115666305 @default.
• W1503115105 cites W2115946363 @default.
• W1503115105 cites W2120099755 @default.
• W1503115105 cites W2120579271 @default.
• W1503115105 cites W2126969449 @default.
• W1503115105 cites W2130387461 @default.
• W1503115105 cites W2130730925 @default.
• W1503115105 cites W2136403658 @default.
• W1503115105 cites W2153416109 @default.
• W1503115105 cites W2157348078 @default.
• W1503115105 cites W2217228022 @default.
• W1503115105 cites W2404249090 @default.
• W1503115105 cites W2407523432 @default.
• W1503115105 cites W2409444226 @default.
• W1503115105 cites W2411566241 @default.
• W1503115105 cites W2414042855 @default.
• W1503115105 cites W2414486861 @default.
• W1503115105 cites W2418014937 @default.
• W1503115105 cites W2418181597 @default.
• W1503115105 cites W2418914842 @default.
• W1503115105 cites W2465933535 @default.
• W1503115105 cites W2466104679 @default.
• W1503115105 cites W2473979892 @default.
• W1503115105 cites W2571766406 @default.
• W1503115105 cites W273205602 @default.
• W1503115105 cites W3183766821 @default.
• W1503115105 cites W4206651960 @default.
• W1503115105 cites W62719132 @default.
• W1503115105 cites W689713 @default.
• W1503115105 cites W74845281 @default.
• W1503115105 cites W77958814 @default.
• W1503115105 cites W917680005 @default.
• W1503115105 cites W140389026 @default.
• W1503115105 doi "https://doi.org/10.1002/14651858.cd011380.pub2" @default.
• W1503115105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6397947" @default.
• W1503115105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30828791" @default.
• W1503115105 hasPublicationYear "2019" @default.
• W1503115105 type Work @default.
• W1503115105 sameAs 1503115105 @default.
• W1503115105 citedByCount "17" @default.
• W1503115105 countsByYear W15031151052018 @default.
• W1503115105 countsByYear W15031151052019 @default.
• W1503115105 countsByYear W15031151052020 @default.
• W1503115105 countsByYear W15031151052021 @default.
• W1503115105 countsByYear W15031151052022 @default.
• W1503115105 countsByYear W15031151052023 @default.
• W1503115105 crossrefType "journal-article" @default.
• W1503115105 hasAuthorship W1503115105A5039039691 @default.
• W1503115105 hasAuthorship W1503115105A5043608283 @default.
• W1503115105 hasAuthorship W1503115105A5046401336 @default.
• W1503115105 hasAuthorship W1503115105A5054459051 @default.
• W1503115105 hasBestOaLocation W15031151052 @default.
• W1503115105 hasConcept C118552586 @default.
• W1503115105 hasConcept C126322002 @default.
• W1503115105 hasConcept C142724271 @default.

• next